This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Injecting Urgency Into Anaphylaxis Management: Achieving Optimal Care

Injecting Urgency Into Anaphylaxis Management: Achieving Optimal Care


Patient Case Study

Time to Complete

30 minutes


March 15, 2016


July 31, 2017
Add to Queue

Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Mylan Pharmaceuticals

Program Description

Anaphylaxis, an acute, systemic, potentially life-threatening allergic reaction, is so commonly misdiagnosed or underreported that reliable statistics about it are elusive, but its prevalence is increasing. Swift intervention is required, followed by comprehensive follow-up, including development of an emergency action plan. Yet alarmingly wide gaps are documented between usual care and optimal, guidelines-concordant anaphylaxis care. These gaps are apparent among emergency department (ED) personnel as well as allergists, primary care physicians, and others. Anaphylaxis recognition and diagnosis are challenging, familiarity with management guidelines is suboptimal, and too few understand that first-line treatment, whether in a clinical setting or when administered by patients/caregivers, should always be epinephrine. Furthermore, patients frequently get inadequate follow-up, although they require testing to identify triggers, counseling about trigger avoidance, and prescriptions for epinephrine autoinjectors along with clear instructions about why, how, and when to use them.

Intended Audience

Emergency room physicians, allergists, primary care physicians, nurse practitioners, physician assistants, and other clinicians who provide care to patients with a history of, or who are at risk for, anaphylaxis

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Implement current guidelines for recognition, diagnosis, and optimal management of anaphylaxis
  • Adopt the use of injectable epinephrine as the only suitable first-line treatment for anaphylaxis or possible anaphylaxis
  • Provide post-treatment counseling and emergency action plans incorporating epinephrine autoinjectors for at-risk patients and their caregivers

Conflict Of Interest Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


Joseph P. Wood, MD, JD, FACEP, FAAEM
Assistant Professor of Emergency Medicine
Vice Chair, Department of Emergency Medicine
Mayo Clinic
Scottsdale, AZ

Dr. Wood has no disclosures to report with any commercial interest relative to this CME activity.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only those credits commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Mylan Pharmaceuticals and HME do not recommend the use of any agent outside of the labeled indications.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Mylan Pharmaceuticals and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue